We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Draft Guidance Addresses Crossover Risk of Male API Use to Potential Offspring
Draft Guidance Addresses Crossover Risk of Male API Use to Potential Offspring
The FDA wants drugmakers to assess the risks of active pharmaceutical ingredients taken by men on the development of embryos and fetuses of their female partners.